Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease

Ageing Research Reviews

Volumn 6, Issue 1, 2007, Pages 54-63

  McFarlane, Dianne ^a  

^a OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

Synuclein; Equine Cushing's disease; Oxidative stress; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE; PROOPIOMELANOCORTIN;

CLINICAL FEATURE; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE MODEL; DISEASE PREDISPOSITION; DOPAMINERGIC NERVE CELL; HISTOPATHOLOGY; HORSE DISEASE; HUMAN; INTERMEDIATE PITUITARY PARS DYSFUNCTION; LARGE SCALE PRODUCTION; LEWY BODY; NERVE CELL LESION; NERVE DEGENERATION; NEUROENDOCRINE DISEASE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; SEX DIFFERENCE; SHORT SURVEY;

ANIMALS; DISEASE MODELS, ANIMAL; HORSE DISEASES; HORSES; HUMANS; PARKINSON DISEASE; PITUITARY DISEASES; PITUITARY GLAND, INTERMEDIATE;

ANIMALIA; EQUIDAE;

EID: 34247373827     PISSN: 15681637     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arr.2007.02.001     Document Type: Short Survey

References (73)

1. Abraham S., Soundararajan C.C., Vivekanandhan S., and Behari M. Erythrocyte antioxidant enzymes in Parkinson's disease. Indian J. Med. Res. 121 (2005) 111-115
2. Betarbet R., Sherer T.B., and Greenamyre J.T. Animal models of Parkinson's disease. Bioessays 24 (2002) 308-318
3. Betarbet R., Canet-Aviles R.M., Sherer T.B., Mastroberardino P.G., McLendon C., Kim J.H., Lund S., Na H.M., Taylor G., Bence N.F., Kopito R., Seo B.B., Yagi T., Yagi A., Klinefelter G., Cookson M.R., and Greenamyre J.T. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol. Dis. 3 (2006) 1301-1306
4. Bokov A., Chaudhuri A., and Richardson A. The role of oxidative damage and stress in aging. Mech. Ageing Dev. 125 (2004) 811-826
5. Bonifati V., Rizzu P., Squitieri F., Krieger E., Vanacore N., van Swieten J.C., Brice A., van Duijn C.M., Oostra B., Meco G., and Heutink P. DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol. Sci. 24 (2003) 159-160
6. Boujon C.E., Bestetti G.E., Meier H.P., Straub R., Junker U., and Rossi G.L. Equine pituitary adenoma: a functional and morphological study. J. Comp. Pathol. 109 (1993) 163-178
7. Brosnahan M.M., and Paradis M.R. Demographic and clinical characteristics of geriatric horses: 467 cases (1989-1999). J. Am. Vet. Med. Assoc. 223 (2003) 93-98
8. Brosnahan M.M., and Paradis M.R. Assessment of clinical characteristics, management practices, and activities of geriatric horses. J. Am. Vet. Med. Assoc. 223 (2003) 99-103
9. Chaudhuri K.R., Healy D.G., and Schapira A.H. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 5 (2006) 235-245
10. Chiba-Falek O., Lopez G.J., and Nussbaum R.L. Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. Mov. Disord. 21 (2006) 1703-1708
11. Chronwall B.M., Millington W.R., Griffin W.S., Unnerstall J.R., and O'Donohue T.L. Histological evaluation of the dopaminergic regulation of proopiomelanocortin gene expression in the intermediate lobe of the rat pituitary, involving in situ hybridization and [3H]thymidine uptake measurement. Endocrinology 120 (1987) 1201-1211
12. Chu Y., and Kordower J.H. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease?. Neurobiol. Dis. 25 (2007) 134-149
13. Conde J.R., and Streit W.J. Microglia in the aging brain. J. Neuropathol. Exp. Neurol. 65 (2006) 199-203
14. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., and Lansbury Jr. P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 571-576
15. de Rijk M.C., Launer L.J., Berger K., Breteler M.M., Dartigues J.F., Baldereschi M., Fratiglioni L., Lobo A., Martinez-Lage J., Trenkwalder C., and Hofman A. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54 (2000) S21-S23
16. Donaldson M.T., LaMonte B.H., Morresey P., Smith G., and Beech J. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease). J. Vet. Intern. Med. 16 (2002) 742-746
17. Double K.L., and Halliday G.M. New face of neuromelanin. J. Neural Transm. Suppl. 70 (2006) 119-123
18. Doudet D.J., Rosa-Neto P., Munk O.L., Ruth T.J., Jivan S., and Cumming P. Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: a multi-tracer PET study. Neuroimage 30 (2006) 26-35
19. Dunnett S.B., and Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399 (1999) A32-A39
20. Dybdal N.O., Hargreaves K.M., Madigan J.E., Gribble D.H., Kennedy P.C., and Stabenfeldt G.H. Diagnostic testing for pituitary pars intermedia dysfunction in horses. J. Am. Vet. Med. Assoc. 204 (1994) 627-632
21. Emborg M.E., Ma S.Y., Mufson E.J., Levey A.I., Taylor M.D., Brown W.D., Holden J.E., and Kordower J.H. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J. Comp. Neurol. 401 (1998) 253-265
22. Fahn S., and Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 32 (1992) 804-812
23. Feany M.B., and Bender W.W. A Drosophila model of Parkinson's disease. Nature 404 (2000) 394-398
24. Fearnley J.M., and Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 Pt 5 (1991) 2283-2301
25. Frank N., Andrews F.M., Sommardahl C.S., Eiler H., Rohrbach B.W., and Donnell R.L. Evaluation of the combined dexamethasone suppression/thyrotropin-releasing hormone stimulation test for detection of pars intermedia pituitary adenomas in horses. J. Vet. Intern. Med. 20 (2006) 987-993
26. Global Parkinson's Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov. Disord. 17 (2002) 60-67
27. Good P.F., Hsu A., Werner P., Perl D.P., and Olanow C.W. Protein nitration in Parkinson's disease. J. Neuropathol. Exp. Neurol. 57 (1998) 338-342
28. Hardy J., Huaiban C., Cookson M.R., Gwinn-Hardy K., and Singleton A. Genetics of Parkinson's disease and parkinsonism. Ann. Neurol. 60 (2006) 389-398
29. Hoepken H.H., Gispert S., Morales B., Wingerter O., Del Turco D., Mulsch A., Nussbaum R.L., Muller K., Drose S., Brandt U., Deller T., Wirth B., Kudin A.P., Kunz W.S., and Auburger G. Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiol. Dis. 25 (2007) 401-411
30. Hornykiewicz O. The tropical localization and content of noradrenalin and dopamine (3-hydroxytyramine) in the substantia nigra of normal persons and patients with Parkinson's disease. Wien. Klin. Wochenschr. 75 (1963) 309-312
31. Jain S., Wood N.W., and Healy D.G. Molecular genetic pathways in Parkinson's disease: a review. Clin. Sci. 109 (2005) 355-365
32. Jellinger K.A. Lewy body-related alpha-synucleinopathy in the aged human brain. J. Neural Transm. 111 (2004) 1219-1235
33. Keeney P.M., Xie J., Capaldi R.A., and Bennett Jr. J.P. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci. 26 (2006) 5256-5264
34. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka N., Mandel R.J., and Bjorklund A. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 22 (2002) 2780-2791
35. Lakso M., Vartiainen S., Moilanen A.M., Sirvio J., Thomas J.H., Nass R., Blakely R.D., and Wong G. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J. Neurochem. 86 (2003) 165-172
36. Lauwers E., Debyser Z., Van Dorpe J., De Strooper B., Nuttin B., and Baekelandt V. Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathol. 13 (2003) 364-372
37. Li J., Uversky V.N., and Fink A.L. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 40 (2001) 11604-11613
38. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., and Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287 (2000) 1265-1269
39. McCormack A.L., Di Monte D.A., Delfani K., Irwin I., DeLanney L.E., Langston W.J., and Janson A.M. Aging of the nigrostriatal system in the squirrel monkey. J. Comp. Neurol. 471 (2004) 387-395
40. McFarlane D., Sellon D.C., and Gibbs S.A. Age-related quantitative alterations in lymphocyte subsets and immunoglobulin isotypes in healthy horses. Am. J. Vet. Res. 62 (2001) 1413-1417
41. McFarlane D., Dybdal N., Donaldson M.T., Miller L., and Cribb A.E. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction. J. Neuroendocrinol. 17 (2005) 73-80
42. McFarlane D., and Cribb A.E. Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses. Am. J. Vet. Res. 66 (2005) 2065-2072
43. Meulener M.C., Xu K., Thomson L., Ischiropoulos H., and Bonini N.M. Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging. Proc. Natl. Acad. Sci. U.S.A 103 (2006) 12517-12522
44. Micieli G., Tosi P., Marcheselli S., and Cavallini A. Autonomic dysfunction in Parkinson's disease. Neurol. Sci. 24 Suppl. 1 (2003) S32-S34
45. Miller D.W., Hague S.M., Clarimon J., Baptista M., Gwinn-Hardy K., Cookson M.R., and Singleton A.B. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 62 (2004) 1835-1838
46. Millington W.R., Dybdal N.O., Dawson Jr. R., Manzini C., and Mueller G.P. Equine Cushing's disease: differential regulation of β-endorphin processing in tumors of the intermediate pituitary. Endocrinology 123 (1988) 1598-1604
47. Mukaetova-Ladinska E.B., and McKeith I.G. Pathophysiology of synuclein aggregation in Lewy body disease. Mech. Ageing Dev. 127 (2006) 188-202
48. Orth D.N., Holscher M.A., Wilson M.G., Nicholson W.E., Plue R.E., and Mount C.D. Equine Cushing's disease: plasma immunoreactive proopiolipomelanocortin peptide and cortisol levels basally and in response to diagnostic tests. Endocrinology 110 (1982) 1430-1441
49. Pallaske G. Zur Kasuistik Seltnere Geschwülste bei den Haustieren. Zeitschrift für Krebsforschung 36 (1932) 342-353
50. Parker Jr. W.D., and Swerdlow R.H. Mitochondrial dysfunction in idiopathic Parkinson disease. Am. J. Hum. Genet. 62 (1998) 758-762
51. Perkins G.A., Lamb S., Erb H.N., Schanbacher B., Nydam D.V., and Divers T.J. Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide. Equine Vet. J. 34 (2002) 679-685
52. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
53. Prigione A., Begni B., Galbussera A., Beretta S., Brighina L., Garofalo R., Andreoni S., Piolti R., and Ferrarese C. Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: negative correlation with levodopa dosage. Neurobiol. Dis. 23 (2006) 36-43
54. Rainero I., Kaye J.A., May C., Durso R., Katz D.I., Albert M.L., Wolfe N., Pinessi L., Friedland R.P., and Rapoport S.I. α-Melanocyte stimulating homone-like immunoreactivity is increased in cerebrospinal fluid of patients with Parkinson's disease. Arch. Neurol. 45 (1988) 1224-1227
55. Reeves S., Bench C., and Howard R. Ageing and the nigrostriatal dopaminergic system. Int. J Geriatr. Psychiatr 17 (2002) 359-370
56. Saland L.C. The mammalian pituitary intermediate lobe: an update on innervation and regulation. Brain Res. Bull. 54 (2001) 587-593
57. Schott, H.C., Coursen, C.L., Eberhart, S.W., Nachreiner, R.J., Refsal, K.R., Ewart, S.L., Marteniuk, J.V., 2001. The Michigan Cushing's Project. In: Am Assoc Eq Pract, Proceedings of the 19th Symposium, vol. 19, Denver, CO, pp. 22-24.
58. Schott H.C. Pituitary pars intermedia dysfunction: equine Cushing's disease. Vet. Clin. N. Am. Equine Pract. 18 (2002) 237-270
59. Serra J.A., Dominguez R.O., de Lustig E.S., Guareschi E.M., Famulari A.L., Bartolome E.L., and Marschoff E.R. Parkinson's disease is associated with oxidative stress: comparison of peripheral antioxidant profiles in living Parkinson's, Alzheimer's and vascular dementia patients. J. Neural Transm. 108 (2001) 1135-1148
60. Shuster S., Burton J.L., Thody A.J., Plummer N., Goolamali S.K., and Bates D. Melanocyte-stimulating hormone and parkinsonism. Lancet 1 (1973) 768
61. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., and Gwinn-Hardy K. Alpha-synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
62. Sloane J.A., Hollander W., Moss M.B., Rosene D.L., and Abraham C.R. Increased microglial activation and protein nitration in white matter of the aging monkey. Neurobiol. Aging 20 (1999) 395-405
63. Sofic E., Lange K.W., Jellinger K., and Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142 (1992) 128-130
64. Souza J.M., Giasson B.I., Chen Q., Lee V.M., and Ischiropoulos H. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 275 (2000) 18344-18349
65. Swerdlow R.H., Parker W.D., Currie L.J., Bennett J.P., Harrison M.B., Trugman J.M., and Wooten G.F. Gender ratio differences between Parkinson's disease patients and their affected relatives. Parkinsonism Relat. Disord. 7 (2001) 29-133
66. Tanaka M., Kim Y.M., Lee G., Junn E., Iwatsubo T., and Mouradian M.M. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J. Biol. Chem. 279 (2004) 4625-4631
67. Tanner C.M., and Goldman S.M. Epidemiology of Parkinson's disease. Neurol. Clin. 14 (1996) 317-335
68. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G., Albanese A., Nussbaum R., Gonzalez-Maldonado R., Deller T., Salvi S., Cortelli P., Gilks W.P., Latchman D.S., Harvey R.J., Dallapiccola B., Auburger G., and Wood N.W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 (2004) 1158-1160
69. van der Kolk J.H., Kalsbveek H.C., van Garderen E., Wensing T.h., and Breukink H.J. Equine pituitary neoplasia: a clinical report of 21 cases (1990-1992). Vet. Rec. 133 (1993) 594-597
70. van der Eeden S.K., Tanner C.M., Bernstein A.L., Fross R.D., Leimpeter A., Bloch D.A., and Nelson R.D. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol 157 (2003) 1015-1022
71. van der Kolk J.H., Heinrichs M., van Amerongen J.D., Stooker R.C., in de Wal L.J., and van den Ingh T.S. Evaluation of pituitary gland anatomy and histopathologic findings in clinically normal horses and horses and ponies with pituitary pars intermedia adenoma. Am. J. Vet. Res. 65 (2004) 1701-1707
72. Wakabayashi K., and Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur. Neurol. 38 Suppl. 2 (1997) 2-7
73. Winkler A.S., Landau S., and Chaudhuri K.R. Serum prolactin levels in Parkinson's disease and multiple system atrophy. Clin. Auton. Res. 12 (2002) 393-398